糖尿病合併症　鑑別ポイントとベスト管理法

出版社： 中山書店
著者：
発行日： 2011-06-01
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784521733760
電子書籍版： 2011-06-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,040 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,040 円(税込)

購入する

商品紹介

糖尿病治療につきものの「合併症」に焦点を当てた。急性から慢性まで，また三大合併症から大血管合併症，関連するその他の合併症まで多くの合併症を取り上げ，その疾患概念や症状，診断，治療，管理の進め方などを簡潔な記述でまとめた。さらに合併症治療のエビデンスや疾患機序に基づく新規治療法の現況についても解説し，合併症を俯瞰的かつヴィジュアルに理解できる1冊である。

目次

  • 糖尿病合併症　鑑別ポイントとベスト管理法

    ―目次―

    1章　合併症総論
    2章　急性合併症の症状・診断・治療
    3章　三大合併症およびその関連疾患の症状・診断・管理
    4章　大血管合併症およびその関連疾患の症状・診断・管理
    5章　その他の合併症
    6章　合併症治療のエビデンスと今後の展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 合併症総論

P.9 掲載の参考文献
1) 日本臨床内科医会調査研究グループ. 糖尿病性神経障害に関する調査研究 第1報わが国の糖尿病の実態と合併症. 日本臨床内科医会会誌 2001 ; 16 : 167-95.
Medical*Online
2) Zhang X, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010 ; 304 : 649-56.
PubMed
3) 井上修二. 糖尿病診療における検査法の進歩. 日本医事新報 1989 ; 3404 : 3-13.
 
4) Sone H, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicentre randomized controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010 ; 53 : 419-28.
PubMed
5) Rajabally YA. Neuropathy and impaired glucose tolerance : an updated review of the evidence. Acta Neurol Scand 2010 : 1-7.
PubMed
6) Fujishima M, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan : The Hisayama Study. Diabetes 1996 ; 45 (Suppl 3) : S14-6.
 
7) 曽根博仁. JDCSにみる糖尿病の合併症. Seasonal Post 2010 ; 2 : 1-3.
 
8) Burrows NR, et al. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010 ; 33 : 73-7.
 
9) 堀田饒ほか. アンケート調査による日本人糖尿病の死因-1991～2000年の10年間, 18,385名での検討. 糖尿病 2007 ; 50 : 47-61.
 

2章 急性合併症の症状・診断・治療

P.19 掲載の参考文献
1) Kitabchi AE, et al ; American Diabetes Association. Hyperglycemic crises in diabetes. Diabetes Care 2004 ; 27 (Suppl 1) : S94-102.
 
2) Kitabchi AE, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009 ; 32 : 1335-43.
PubMed
・ Wyckoff J, Abrahamson MJ. 糖尿病ケトアシドーシスと高浸透圧性高血糖状態. 金澤康徳ほか監訳. ジョスリン糖尿病学. 第2版. メディカル・サイエンス・インターナショナル ; 2007. pp.989-1002.
 
・ 大原毅. 糖尿病ケトアシドーシス. 日本臨牀 2008 ; 66巻増刊号9 : 63-70.
 
P.23 掲載の参考文献
1) 河西浩一. 高浸透圧性非ケトン性糖尿病こん睡症例の臨床所見-本邦報告例316例の集計より. 最新医学 1984 ; 39 : 2347-57.
 
2) Rosenthal NR, Barrett EJ. An assessment of insulin action in hyperosmolar hyperglycemic nonketotic diabetic patients. J Clin Endocrinol Metab 1985 ; 60 : 607-10.
PubMed
3) Kitabchi AE, et al. Thirty years of personal experience in hyperglycemic crises : diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab 2008 ; 93 : 1541-52.
 
4) Chen HF, et al. Short-term case fatality rate and associated factors among inpatients with diabetic ketoacidosis and hyperglycemic hyperosmolar state : a hospital-based analysis over a 15-year period. Intern Med 2010 ; 49 : 729-37.
 
5) Kitabchi AE, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009 ; 32 : 1335-43.
PubMed
6) Stoner GD. Hyperosmolar hyperglycemic state. Am Fam Physician 2005 ; 71 : 1723-30.
PubMed
7) Brenner ZR. Management of hyperglycemic emergencies. AACN Clin Issues 2006 ; 17 : 56-65.
PubMed
P.27 掲載の参考文献
1) Luft D, et al. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol 1983 ; 80 : 484-9.
PubMed
2) Mizock BA. Lactic acidosis. Dis Mon 1989 ; 35 : 233-300.
PubMed
3) Cohen R, Woods HF. The clinical presentation and classification of lactic acidosis. In : Cohen R, Woods HF, eds. Clinical and Biochemical Aspects of Lactic Acidosis. Blackwell Scientific Publications ; 1976. pp.40-52,
 
4) 河西浩一ほか. 乳酸代謝と乳酸アシドーシス. 臨床病理 1998 ; 46 : 804-12.
Medical*Online
5) Berger W. Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. Horm Metab Res Suppl 1985 ; 15 : 111-5.
PubMed
6) Kraut JA, Madias NE. Metabolic acidosis : pathophysiology, diagnosis and management. Nat Rev Nephrol 2010 ; 6 : 274-85.
PubMed
P.32 掲載の参考文献
1) Servise FJ. Hypoglycemic disorders. N Engl J Med 1995 ; 332 : 1144-52.
 
2) Fanelli C, et al. Relative roles of insulin and hypoglycemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycemia in male and female humans. Diabetologia 1994 ; 37 : 797-807.
PubMed
3) Marks V, Teale JD. Hypoglycemia : factitious and felonious. Endoocrinol Metab Clin North Am 1999 ; 28 : 579-601.
 
・ 日本糖尿病学会編. 糖尿病専門医研修ガイドブック. 改訂第4版. 診断と治療社 ; 2009.
 
・ Guettier JM, Gorden P. Hypoglycemia. Endoocrinol Metab Clin North Am 2006 ; 35 : 753-66.
 
・ Murad MH, et al. Clinical review : Drug-induced hypoglycemia : a systematic review. J Clin Endocrinol Metab 2009 ; 94 : 741-5.
PubMed
P.36 掲載の参考文献
1) 内潟安子ほか. 自発性低血糖症の原因疾患の全国調査-第一報. 糖尿病 2010 ; 53 : S271.
 
2) 平田幸正ほか. インスリン自己免疫症候群を示した自発性低血糖症の1例. 糖尿病 1970 ; 13 : 312-20.
 
3) Uchigata Y, et al. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 1992 ; 339 : 393-4.
PubMed
4) Uchigata Y, et al. Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes 1995 ; 44 : 1227-32.
 
5) Miyamura N, et al. A case of insulin autoimmune syndrome with HLA DRB1*0404 : impact on the hypothesis for the molecular pathogenesis involving DRB1 molecules. Diabet Med 2006 ; 23 : 104-5.
PubMed
6) Matsushita S, et al. Allele specificity of structural requirement for peptides bound to HLADRB1*0405 and -DRB1*0406 complexes : implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med 1994 ; 180 : 873-83.
PubMed
7) Konrad D. Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acidreduction or oxidation? Antioxid Redox Signal 2005 ; 7 : 1032-9.
PubMed
8) Ziegler D, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid : a meta-analysis. Diabet Med 2004 ; 21 : 114-21.
PubMed
9) Furukawa N, et al. Possible relevance of alpha lipoic acid contained in a health supplement in a case of insulin autoimmune syndrome. Diabetes Res Clin Pract 2007 ; 75 : 366-7.
 
10) 中島千鶴ほか. αリポ酸が誘因と推察されたインスリン自己免疫症候群の1例. 糖尿病 2007 ; 50 : 623-6.
 
P.41 掲載の参考文献
1) 米田真康ほか. 糖尿病患者における感染症の特徴およびその対策. 糖尿病 2007 ; 50 : 137-43.
 
2) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会編. 成人市中肺炎診療ガイドライン. 日本呼吸器学会 ; 2007.
 
3) Smitheran KO, Peacock JE Jr. Infectious emergencies in patients with diabetes mellitus. Med Clin North Am 1995 ; 79 : 53-77.
 
4) Brunkhorst FM, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008 ; 358 : 125-39.
PubMed
5) Preiser JC, et al. A prospective randomized multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units : the Glucontrol study. Intensive Care Med 2009 ; 35 : 1738-48.
PubMed
6) Dellinger RP, et al. Surviving Sepsis Campaign : international guidelines for management of severe sepsis and septic shock : 2008. Crit Care Med 2008 ; 36 : 296-327.
PubMed
7) NICE-SUGER Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009 ; 360 : 1283-97.
 

3章 三大合併症およびその関連疾患の症状・診断・管理

P.47 掲載の参考文献
・ 大沼郁子. 糖尿病網膜症の病態と分類. 眼科 2004 ; 46 : 147-56.
 
・ 荒木栄一ほか. 糖尿病網膜症の分子病態学-代謝異常を中心に. あたらしい眼科 2010 ; 27 : 1175-84.
 
・ 川崎良. 糖尿病網膜症の重症度分類. 山下英俊, 川崎良編. 糖尿病網膜症-専門医によるベストアドバイス. 診断と治療社 ; 2003. pp.47-59.
 
・ Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001 ; 17 : 436-43.
PubMed
・ Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002 ; 251 : 87-101.
PubMed
・ Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998 ; 47 : 859-66.
PubMed
P.53 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
2) Ohkubo Y, Kishikawa H, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
3) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
4) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
5) Chaturvedi N, Porta M, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes : randomized, placebo-controlled trials. Lancet 2008 ; 372 : 1394-402.
PubMed
6) Sjolie AK, Klein R, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomized placebo-controlled trial. Lancet 2008 ; 372 : 1385-93.
PubMed
7) Keech AC, Mitchell P, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study) : a randomized controlled trial. Lancet 2007 ; 370 : 1687-97.
PubMed
8) Gaede P, Lund-Andersen H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
PubMed
9) ACCORD Study Group ; ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 ; 363 : 233-44.
 
・ Davis, MD, Fisher, MR, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss : Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998 ; 39 : 233-52.
PubMed
・ Mohamed Q, Gillies MC, et al. Management of diabetic retinopathy : a systematic review. JAMA 2007 ; 298 : 902-16.
PubMed
・ Cheung N, Mitchell P, et al. Diabetic retinopathy. Lancet 2010 ; 376 : 124-36.
PubMed
P.57 掲載の参考文献
1) The Japanese Society of Ophthalmic Diabetology, Subcommittee on the Study of Diabetic Retinopathy Treatment : Multi-center randomized clinical trial on retinal photocoagulation for preproliferative diabetic retinopathy. Jpn J of Ophthalmol. in press.
 
2) Photocoagulation treatment of proliferative diabetic retinopathy : the second report of diabetic retinopathy study findings. Ophthalmology 1978 ; 85 : 82-106.
PubMed
3) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991 ; 98 (5 Suppl) : 766-85.
 
4) Early worsening of diabetic retinopathy in the Diabetes Control and Complication Trial. Arch Ophthalmol 1998 ; 116 : 874-86.
PubMed
P.63 掲載の参考文献
1) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987 ; 94 : 761-74.
 
2) Bresnick GH. Diabetic macular edema. A review. Ophthalmology 1986 ; 93 : 989-97.
PubMed
3) Peyman GA, Bok D. Peroxidase diffusion in the normal and laser-coagulated primate retina. Invest Ophthalmol 1972 ; 11 : 35-45.
PubMed
4) Martidis A, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002 ; 109 : 920-7.
PubMed
5) Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002 ; 86 : 363-5.
PubMed
6) Miyamoto K, et al. Vascular endothelial growth factor (VEGF) -induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000 ; 156 : 1733-9.
PubMed
7) Lewis H, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992 ; 99 : 753-9.
PubMed
8) Cunningham ET Jr, et al ; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005 ; 112 : 1747-57.
 
9) Michaelides M, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data : report 2. Ophthalmology 2010 ; 117 : 1078-86.
PubMed
10) Massin P, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study) : a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010 ; 33 : 2399-405.
PubMed
P.69 掲載の参考文献
1) Brown GC, et al. Neovascular glaucoma. Etiologic considerations. Ophthalmology 1984 ; 91 : 315-20.
PubMed
2) Iliev ME, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006 ; 142 : 1054-6.
PubMed
3) Wakabayashi T, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008 ; 115 : 1571-80, e1-3.
 
4) Takihara Y, et al. Combined Intravitreal Bevacizumab and Trabeculectomy With Mitomycin C Versus Trabeculectomy With Mitomycin C Alone for Neovascular Glaucoma. J Glaucoma 2010.
 
5) Miki A, et al. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol 2008 ; 92 : 1431-3.
PubMed
6) Saito Y, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol 2010 ; 88 : 96-102.
PubMed
7) Sivak-Callcott JA, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001 ; 108 : 1767-76.
PubMed
P.75 掲載の参考文献
1) Klein BE, et al. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities : the Beaver Dam Eye Study. Am J Ophthalmol 1998 ; 126 : 782-90.
PubMed
2) Leske MC, et al. Diabetes, hypertension, and central obesity as cataract risk factors in a black population. The Barbados Eye Study. Ophthalmology 1999 ; 106 : 35-41.
 
3) Hennis A, et al. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. Arch Ophthalmol 2004 ; 122 : 525-30.
PubMed
4) Oishi N, et al. Correlation between adult diabetic cataracts and red blood cell aldose reductase levels. Invest Ophthalmol Vis Sci 2006 ; 47 : 2061-4.
PubMed
5) Kato S, et al. Influence of phacoemulsification and intraocular lens implantation on the course of diabetic retinopathy. J Cataract Refract Surg 1999 ; 25 : 788-93.
PubMed
6) Suto C, et al. Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol 2006 ; 124 : 38-45.
PubMed
7) Morikubo S, et al. Corneal changes after small-incision cataract surgery in patients with diabetes mellitus. Arch Ophthalmol 2004 ; 122 : 966-9.
PubMed
8) Kato S, et al. Anterior capsular contraction after cataract surgery in eyes of diabetic patients. Br J Ophthalmol 2001 ; 85 : 21-3.
PubMed
9) Hayashi K, et al. Posterior capsule opacification after cataract surgery in patients with diabetes mellitus. Am J Ophthalmol 2002 ; 134 : 10-6.
PubMed
10) Takamura Y, et al. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009 ; 116 : 1151-7.
PubMed
P.81 掲載の参考文献
1) Drury PL, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus : the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011 ; 54 : 32-43.
PubMed
2) Jefferson JA, et al. Proteinuria in diabetic kidney disease : a mechanistic viewpoint. Kidney Int 2008 ; 74 : 22-36.
PubMed
3) Adler AI, et al ; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 ; 63 : 225-32.
PubMed
4) Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004 ; 351 : 1296-305. Erratum in : N Engl J Med 2008 ; 18 : 4.
 
5) アメリカ腎臓財団 (NKF). K/DOQI (kidney disease outcome quality initiative) 慢性腎臓病ガイドライン. 2002.
 
6) Matheson A, et al. Urinary biomarkers involved in type 2 diabetes : a review. Diabetes Metab Res Rev 2010 ; 26 : 150-71.
PubMed
7) Araki S, et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 2010 : 33 : 1805-10.
PubMed
P.86 掲載の参考文献
1) 日本腎臓学会編. CKD診療ガイド 2009. 東京医学社 ; 2009.
 
2) Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992 ; 20 : 533-47.
PubMed
3) Parving HH, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992 ; 41 : 758-62.
PubMed
4) Schwartz MM, et al. Renal pathology patterns in type II diabetes mellitus : relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998 ; 13 : 2547-52.
 
5) Mauer SM, et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984 ; 74 : 1143-55.
PubMed
6) Hayashi H, et al. An electron microscopic study of glomeruli in Japanese patients with non-insulin dependent diabetes mellitus. Kidney Int 1992 ; 41 : 749-57.
PubMed
7) Chavers BM, et al. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 1989 ; 320 : 966-70.
PubMed
8) Moriya T, et al. Urinary albumin as an indicator of diabetic nephropathy lesions in Japanese type 2 diabetic patients. Nephron 2002 ; 91 : 292-9.
PubMed
9) Perkins BA, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003 ; 348 : 2285-93.
PubMed
10) Gaede P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004 ; 19 : 2784-8.
 
P.94 掲載の参考文献
1) Devins GM, et al. Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease. Am J Kidney Dis 2003 ; 42 : 693-703.
PubMed
2) Inaguma D, et al. Effect of an educational program on the predialysis period for patients with chronic renal failure. Clin Exp Nephrol 2006 ; 10 : 274-8.
PubMed
3) Martinez-Ramirez HR, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy : a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis 2006 ; 47 : 78-87.
 
4) Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 ; 345 : 851-60.
PubMed
5) de Zeeuw D, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy : lessons from RENAAL. Kidney Int 2004 ; 65 : 2309-20.
PubMed
6) Mann JF, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study) : a multicentre, randomised, doubleblind, controlled trial. Lancet 2008 ; 372 : 547-53.
 
7) Levey AS, et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis 1996 ; 27 : 652-63.
PubMed
8) Tonelli M, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005 ; 112 : 171-8.
 
・ 日本腎臓学会編. エビデンスに基づくCKD診療ガイドライン 2009. 東京医学社 ; 2009.
 
・ 富野康日己. ファーマナビゲーター慢性腎不全・透析編. メディカルレビュー社 ; 2004.
 
P.102 掲載の参考文献
1) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況 (2009年12月31日現在).
 
2) 原茂子ほか. 末期糖尿病性腎症に対する透析療法と問題点. 日本臨牀 2002 ; 60 (Suppl 10) : 306-15.
 
3) Adler AI, et al. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 ; 63 : 225-32.
PubMed
4) Tanaka K, et al. Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic patients : critical level of the estimated glomerular filtration rate and the significance of hyperuricemia. Clin Exp Nephrol 2011. [Epub ahead of print]
 
5) 原茂子, 星野純一. 末期糖尿病性腎症に対する透析療法と問題点. 日本臨牀 2008 ; 66 (増刊号) : 266-73.
 
6) 香取秀幸ほか. 糖尿病透析患者の冠動脈疾患の管理基準. 透析会誌 2004 ; 37 : 1561-3.
 
7) Jono S, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000 ; 87 : E10-7.
PubMed
8) Hayashino Y, et al. Diabetes, glycaemic control and mortality risk in patients on hemodialysis : the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007 ; 50 : 1170-7.
PubMed
9) Inaba M, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes : effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007 ; 18 : 896-903.
PubMed
10) Santoro A, et al. Acetate-free biofiltration. Contrib Nephrol 2007 ; 158 : 138-52.
PubMed
11) Hosino J, et al. Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. Circ J 2007 ; 71 : 1193-8.
 
P.107 掲載の参考文献
1) Ewing DJ, et al. The natural history of diabetic autonomic neuropathy. QJ Med 1980 ; 49 : 95-108.
 
2) Dyck PJ. Detection, characterization, and staging of polyneuropathy : assessed in diabetics. Muscle Nerve 1988 ; 11 : 21-32.
PubMed
3) Consensus statement. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes 1988 ; 37 : 1000-4.
 
4) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害 (distal symmetric polyneuropathy) の簡易診断基準 (小改訂版). 末梢神経 2001 ; 12 : 225-7.
 
5) Feldman EL, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994 ; 17 : 1281-9.
PubMed
6) Hotta N, et al. Use of the C64 quantitative tuning fork and the effect of niceritrol in diabetic neuropathy. Clin Ther 1994 ; 16 : 1007-15.
PubMed
P.113 掲載の参考文献
1) 安田斎. 糖尿病末梢神経障害の診断と病期分類. プラクティス 2008 ; 25 : 394-9.
Medical*Online
2) Apfel SC, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trilas. J Neurol Sci 2001 ; 189 : 3-5.
 
3) Chan YC, et al. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev 2009 ; (3) : CD006521.
PubMed
4) Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain : an update and effect related to mechanism of drug action. Pain 1999 ; 83 : 389-400.
PubMed
5) ガイドライン策定委員会. 糖尿病神経障害の治療. 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010. pp.103-14.
 
6) Pfeifer MA, et al. A highly successful and novel model for tretment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993 ; 16 : 1103-15.
 
7) O'Connor AB, Dworkin RH. Treatment of neuropathic pain : an overview of recent guidelines. Am J Med 2009 ; 122 (10 Suppl) : S22-32.
 
8) Dworkin RH, et al. Pharmacologic management of neuropathic pain : evidencebased recommendations. Pain 2007 ; 132 : 237-51.
PubMed
9) Yasuda H, et al. Superiority of duloxetine to placebo in improving diabetic neuropathic pain : Results of a randomized controlled trial in Japan. J Diabetes Invest 2011 ; 2 : 132-9.
 
10) Gilron I, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005 ; 352 : 1324-34.
 
P.118 掲載の参考文献
1) Freeman R. Autonomic peripheral neuropathy. Lancet 2005 ; 365 : 1259-70.
PubMed
2) 高橋良当ほか. 糖尿病性自律神経障害とその治療. 日本臨牀 2008 ; 66 (増刊9) : 213-6.
 
3) 糖尿病神経障害の治療. 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010. pp.103-11.
 
4) Fujiwara Y, et al. Thermographic measurement of skin temperature recovery time of extremities in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000 ; 108 : 463-9.
PubMed
5) Matsutomo R, et al. Assessment of peripheral neuropathy using measurement of the current perception threshold with the neurometer in patients with type 2 diabetes mellitus. J Int Med Res 2005 ; 33 : 442-53.
PubMed
6) 若林貞男ほか. 起立性低血圧を有する2型糖尿病患者における24時間心拍変動パワースペクトル解析. 糖尿病 2006 ; 49 : 19-26.
 
7) Wheeler T, Watkins PJ. Cardiac denervation in diabetes. Br Med J 1973 ; 4 : 584-6.
PubMed
8) Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
PubMed
9) Erbas T, et al. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993 ; 16 : 1511-4.
PubMed
10) Rendell MS, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes : a randomized controlled trial. JAMA 1999 ; 281 : 421-6.
PubMed
P.126 掲載の参考文献
1) Boulton AJ, et al. Diabetic somatic neuropathies. Diabetes Care 2004 ; 27 : 1458-86.
PubMed
2) Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies : new insights into pathophysiology and treatment. Muscle Nerve 2002 ; 25 : 477-91.
PubMed
3) Tracy JA, Windebank AJ. Microvasculitis in diabetic lumbosacral radiculoplexus neuropathy. J Clin Neuromuscul Dis 2009 ; 11 : 44-8.
 
4) Zochodne DW. Diabetes mellitus and the peripheral nervous system : manifestations and mechanisms. Muscle Nerve 2007 ; 36 : 144-66.
PubMed
5) Bansal V, et al. Diabetic neuropathy. Postgrad Med J 2006 ; 82 : 95-100.
PubMed
6) Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med 2009 ; 10 : 1476-80.
PubMed
7) Kawamura N, et al. Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. Acta Neuropathol 2008 ; 115 : 231-9.
PubMed
・ Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005 ; 10 : 220-8.
 

4章 大血管合併症およびその関連疾患の症状・診断・管理

P.132 掲載の参考文献
1) 日本脳ドック学会脳ドックの新ガイドライン作成委員会編. 脳ドックのガイドライン 2008. 改訂第3版. 響文社 ; 2008.
 
2) 篠原幸人ほか編. 脳卒中治療ガイドライン 2009. 協和企画 ; 2009.
 
3) Vermeer SE, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population : the Rotterdam Scan Study. Stroke 2003 ; 34 : 1126-9.
PubMed
4) Bernick C, et al. Silent MRI infarcts and the risk of future stroke : the cardiovascular health study. Neurology 2001 ; 57 : 1222-9.
PubMed
5) Kitamura A, et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke 2004 ; 35 : 2788-94.
PubMed
6) Kawamori R, et al. Prevalence of carotid atherosclerosis in diabetic patients. Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 1992 ; 15 : 1290-4.
PubMed
P.139 掲載の参考文献
1) Doi Y, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 2010 ; 41 : 203-9.
 
2) 藤島正敏. 高齢者の心血管病-久山町研究から. 日老医誌 1999 ; 36 : 16-21.
 
3) Doi Y, et al. Proposed criteria for metabolic syndrome in Japanese based on prospective evidence : the Hisayama Study. Stroke 2009 ; 40 : 1187-94.
PubMed
4) 篠原幸人ほか編. 脳卒中治療ガイドライン 2009. 協和企画 ; 2010.
 
5) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
6) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med 2008 ; 358 : 2545-59.
 
7) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med 2008 ; 358 : 2560-72.
 
8) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
9) Tajima N, et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes : diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008 ; 199 : 455-62.
PubMed
10) Ogawa H, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial. JAMA 2008 ; 300 : 2134-41.
PubMed
11) Wilcox R, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke : results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 ; 38 : 865-73.
 
12) Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence : a systematic review and meta-analysis. Int Arch Med 2009 ; 2 : 30.
PubMed
13) Amarenco P, et al ; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Eng J Med 2006 ; 355 : 549-59.
PubMed
14) Shinohara Y, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008 ; 26 : 63-70.
PubMed
15) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン 2009. ライフサイエンス出版 ; 2009.
 
16) 日本動脈硬化学会. 動脈硬化性疾患予防のための脂質異常症治療ガイド 2008年版. 協和企画 ; 2008
 
17) Sacco RL, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack : a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stoke : co-sponsored by Council on Cardiovascular Radiology and Intervention : the American Academy of Neurology affirms the value of this guideline. Circulation 2006 ; 113 : e409-49.
 
18) Gaede P, Lund-Andersen H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
PubMed
P.146 掲載の参考文献
1) 脳出血の予防. 篠原幸人ほか編. 脳卒中治療ガイドライン 2009. 協和企画 ; 2009. pp.132-5.
 
2) Janghorbani M, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes : the Nurses' Health Study. Diabetes Care 2007 ; 30 : 1730-5.
PubMed
3) Cordonnier C, et al. Spontaneous brain microbleeds : systematic review, subgroup analyses and standards for study design and reporting. Brain 2007 ; 130 : 1988-2003.
PubMed
4) Lovelock CE, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage : a systematic review of published and unpublished studies. Stroke 2010 ; 41 : 1222-8.
PubMed
5) 脳卒中超急性期の呼吸・循環・代謝管理 (3) 栄養. 篠原幸人ほか編. 脳卒中治療ガイドライン 2009. 協和企画 ; 2009. p.9.
 
6) Urabe T, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke 2009 ; 40 : 1289-95.
PubMed
7) Quinn TJ, Lees KR. Hyperglycaemia in acute stroke-to treat or not to treat. Cerebrovasc Dis 2009 ; 27 (Suppl 1) : 148-55.
PubMed
8) Candelise L, et al. Prognostic significance of hyperglycemia in acute stroke. Arch Neurol 1985 ; 42 : 661-3.
PubMed
9) Hosomi N, et al. Predictors of intracerebral hemorrhage severity and its outcome in Japanese stroke patients. Cerebrovasc Dis 2009 ; 27 : 67-74.
PubMed
10) Stead LG, et al. Emergency Department hyperglycemia as a predictor of early mortality and worse functional outcome after intracerebral hemorrhage. Neurocrit Care 2010 ; 13 : 67-74.
PubMed
11) Pittas AG, et al. Insulin therapy for critically ill hospitalized patients : a meta-analysis of randomized controlled trials. Arch Intern Med 2004 ; 164 : 2005-11.
PubMed
P.153 掲載の参考文献
1) Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients : a systematic review of prospective trials. J Alzheimers Dis 2009 ; 16 : 677-85.
PubMed
2) Ott A, et al. Diabetes mellitus and the risk of dementia : The Rotterdam Study. Neurology 1999 ; 53 : 1937-42.
PubMed
3) Craft S, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease : relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998 ; 50 : 164-8.
PubMed
4) Craft S. Insulin resistance and Alzheimer's disease pathogenesis : potential mechanisms and implications for treatment. Curr Alzheimer Res 2007 ; 4 : 147-52.
PubMed
5) Watson GS, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone : a preliminary study. Am J Geriatr Psychiatry 2005 ; 13 : 950-8.
PubMed
6) Reger MA, et al. Effects of intranasal insulin on cognition in memory-impaired older adults : modulation by APOE genotype. Neurobiol Aging 2006 ; 27 : 451-8.
PubMed
7) Biessels GJ, et al. Risk of dementia in diabetes mellitus : a systematic review. Lancet Neurol 2006 ; 5 : 64-74.
PubMed
・ Schwarzt MW, Porte D Jr. Diabetes, obesity, and the brain. Science 2005 ; 307 : 375-9.
 
・ Craft S, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease : relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998 ; 50 : 164-8.
PubMed
・ Fernandez-Gamba A, et al. Insulin-degrading enzyme : structure-function relationship and its possible roles in health and disease. Curr Pharm Des 2009 ; 15 : 3644-55.
PubMed
P.161 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
4) Ray KK, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus : a meta-analysis of randomized controlled trials. Lancet 2009 ; 373 : 1765-72.
PubMed
5) Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
PubMed
6) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
7) Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
PubMed
8) Chiasson JL, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 2003 ; 290 : 486-94.
PubMed
9) Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomized controlled trial. Lancet 2005 ; 366 : 1279-89.
PubMed
10) Mahmud E, et al. Clinical efficacy of drug-eluting stents in diabetic patients : a meta-analysis. J Am Coll Cardiol 2008 ; 51 : 2385-95.
PubMed
11) Daemen J, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus : 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol 2008 ; 52 : 1957-67.
 
12) Banning AP, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease : comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010 ; 55 : 1067-75.
 
P.166 掲載の参考文献
1) Chew EY, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol 1995 ; 113 : 52-5.
PubMed
2) ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992 ; 268 : 1292-300.
PubMed
3) Belch J, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial : factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 ; 337 : a1840.
PubMed
4) Ogawa H, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial. JAMA 2008 ; 300 : 2134-41.
PubMed
5) Antithrombotic Trialists' (ATT) Collaboration, et al. Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009 ; 373 : 1849-60.
PubMed
6) Pignone M, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes : a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010 ; 121 : 2694-701.
 
P.169 掲載の参考文献
1) Nishimura T, et al. Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT : J-ACCESS study. Eur J Nucl Med Mol Imaging 2008 ; 35 : 319-28.
PubMed
2) Yamasaki Y, et al. Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes : the J-ACCESS 2 investigation. Diabetes Care 2010 ; 33 : 2320-6.
 
3) Bots ML, et al. Common carotid intima-media thickness and risk of stroke and myocardial infaction : the Rotterdam Study. Circulation 1997 ; 96 : 1432-7.
 
4) Hodis HN, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998 ; 128 : 262-9.
PubMed
5) Shinoda-Tagawa T, et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia 2002 ; 45 : 188-94.
PubMed
6) Cavalot F, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women : lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006 ; 91 : 813-9.
 
7) Hanefeld M, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients : meta-analysis of seven long-term studies. Eur Heart J 2004 ; 25 : 10-6.
PubMed
8) NAVIGATOR Study Group, Holman RR, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1463-76.
 
9) Yamasaki Y, et al. Long-Term Effects of Pioglitazone on Carotid Atherosclerosis in Japanese Patients with Type 2 Diabetes without a Recent History of Macrovascular Morbidity. J Atheroscler Thromb 2010 ; 17 : 1132-40.
PubMed
10) Nissen SE, et al ; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis : the ASTEROID trial. JAMA 2006 ; 295 : 1556-65.
 
11) Mita T, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007 ; 191 : 162-7.
PubMed
12) Pitt B, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 ; 102 : 1503-10.
PubMed
13) Ogawa H, et al ; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes : a randomized controlled trial. JAMA 2008 ; 300 : 2134-41.
PubMed
14) Kodama M, et al. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res 2000 ; 97 : 239-45.
PubMed
15) Katakami N, et al. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus : principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study : a randomized trial. Circulation 2010 ; 121 : 2584-91.
PubMed
16) Shinohara Y, et al ; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirincontrolled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010 ; 9 : 959-68.
PubMed
P.176 掲載の参考文献
1) Rubler S, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972 ; 30 : 595-602.
PubMed
2) MacDonald MR, et al ; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure : an analysis of the Candesartan in Heart failure : Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008 ; 29 : 1377-85.
PubMed
3) Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007 ; 115 : 3213-23.
PubMed
4) Liu JE, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults : the Strong Heart Study. J Am Coll Cardiol 2001 ; 37 : 1943-9.
PubMed
5) Shishehbor MH, et al. Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease. Am J Cardiol 2003 ; 91 : 1514-7.
PubMed
6) Herrero P, et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006 ; 47 : 598-604.
PubMed
7) Candido R, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003 ; 92 : 785-92.
PubMed
8) Shindler DM, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996 ; 77 : 1017-20.
PubMed
9) Haas SJ, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A metaanalysis of large-scale clinical trials. Am Heart J 2003 ; 146 : 848-53.
PubMed
P.181 掲載の参考文献
1) Norgren L, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007 ; 45 (Suppl S) : S5-67.
 
2) Adler AI, et al. UKPDS 59 : hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002 ; 25 : 894-9.
PubMed
3) Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994 ; 1 : 333-9.
PubMed
4) Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995 ; 274 : 975-80.
 
P.188 掲載の参考文献
1) Norgren L, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007 ; 45 (Suppl S) : S5-67.
 
2) Henry TD, et al. VEGF in ischemic for vascular angiogenesis (VIVA) trial : one year follow up. Circulation 2000 ; 102 : II 309.
 
3) Marui A, et al. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel : an initial report of the phase I-IIa study. Circ J 2007 ; 71 : 1181-6.
PubMed
4) Rajagopalan S, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease : a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003 ; 108 : 1933-8.
PubMed
5) Nikol S, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008 ; 16 : 972-8.
 
6) Morishita R, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol. 2011 ; 31 : 713-20.
PubMed
7) Powell RJ, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008 ; 118 : 58-65.
PubMed
8) Shigematsu H, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010 ; 17 : 1152-61.
PubMed
9) Tateishi-Yuyama E, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells : a pilot study and a randomized controlled trial. Lancet 2002 ; 360 : 427-35.
 
10) Matoba S, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008 ; 156 : 1010-8.
PubMed
P.193 掲載の参考文献
1) Purewal TS, et al. Lower limb venous pressure in diabetic neuropathy. Diabetes Care 1995 ; 18 : 377-81.
PubMed
2) Armstrong DG, et al. Skin temperature monitoring reduces the risk for diabetic foot ulceration in high-risk patients. Am J Med 2007 ; 120 : 1042-6.
PubMed
3) Attinger CE, et al. Debridement of the Diabetic Foot. In : Armstrong DG, Lavery LA, eds. Clinical Care of the Diabetic Foot. 2nd ed. American Diabetes Association ; 2010. pp.49-60.
 
4) Edmonds ME, Foster AVM. Managing the Diabetic Foot. 2nd ed. Blackwell Publishing ; 2005/内村功監訳. 糖尿病足病変研究会訳. 糖尿病フットケアハンドブック. シュプリンガー・ジャパン ; 2006. pp.76-7.
 
5) International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot. 1999/内村功ほか監訳. インターナショナル・コンセンサス糖尿病足病変. 医歯薬出版 ; 2000.
 

5章 その他の合併症

P.201 掲載の参考文献
1) 日本肝臓学会編. NASH・NAFLDの診療ガイド 2010. 文光堂 ; 2010.
 
2) Shindo N, et al. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in a novel spontaneous mouse model. J Hepatol 2010 ; 52 : 903-12.
 
3) Adams LA, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes : a community-based cohort study. Am J Gastroenterol 2010 ; 105 : 1567-73.
PubMed
4) Musso G, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010 ; 52 : 79-104.
 
5) Kobayashi M, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007 ; 56 : 239-47.
PubMed
6) Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010 ; 362 : 1675-85.
 
・ Fierbinteanu-Braticevici C, et al. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010 ; 16 : 4784-91.
PubMed
P.206 掲載の参考文献
1) Emrich LJ, et al. Periodontal disease in non-insulin dependent diabetes mellitus. J Periodontol 1991 ; 62 : 123-31.
PubMed
2) Grossi SG. Treatment of periodontal disease and control of diabetes : an assessment of the evidence and need for future research. Ann Periodontol 2001 ; 6 : 138-45.
PubMed
3) Iwamoto Y, et al. The effect of antimicrobial periodontal treatment of circulating tumor necrosis factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. J Periodontol 2001 ; 72 : 774-8.
PubMed
4) Saremi A, et al. Periodontal disease and mortality in type 2 diabetes. Diabetes Care 2005 ; 28 : 27-32.
PubMed
5) 日本歯周病学会編. 歯周病の検査・診断・治療計画の指針 2008. 医歯薬出版 ; 2009.
 
・ 日本歯科医学会監修. 糖尿病患者に対する歯周治療ガイドライン. 精堂印刷 ; 2009.
 
P.211 掲載の参考文献
1) 岸本暢将編. すぐに使えるリウマチ・膠原病診療マニュアル. 羊土社 ; 2009.
 
2) Firestein GS, et al. Kelley's Textbook of Rheumatology. 8th ed. WB Saunders ; 2008.
 
3) Cagliero E, et al. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. Am J Med 2002 ; 112 : 487-90.
PubMed
4) Rosenbloom AL, Silverstein JH. Connective tissue and joint disease in diabetes mellitus. Endocrinol Metab Clin North Am 1996 ; 25 : 473-83.
PubMed
5) Papanas N, Maltezos E. The diabetic hand : a forgotten complication? J Diabetes Complications 2010 ; 24 : 154-62.
 
6) Trojian TH, Chu SM. Dupuytren's disease : diagnosis and treatment. Am Fam Physician 2007 ; 76 : 86-9.
PubMed
7) Siegel LB, et al. Adhesive capsulitis : a sticky issue. Am Fam Physician 1999 ; 59 : 1843-52.
PubMed
P.218 掲載の参考文献
1) Janghorbani M, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007 ; 166 : 495-505.
PubMed
2) Heath H 3rd, et al. Diabetes mellitus and risk of skeletal fracture. N Engl J Med 1980 ; 303 : 567-70.
PubMed
3) Melton LJ 3rd, et al. Fracture risk in type 2 diabetes : update of a populationbased study. J Bone Miner Res 2008 ; 23 : 1334-42.
PubMed
4) Inaba M, et al. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005 ; 76 : 256-60.
PubMed
5) Lenchik L, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003 ; 33 : 646-51.
PubMed
6) Saito M, et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006 ; 17 : 1514-23.
PubMed
7) Kraukauer JC, et al. Bone loss and bone turnover in diabetes. Diabetes 1995 ; 44 : 775-82.
 
8) Inaba M, et al. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 1995 ; 10 : 1050-6.
 
9) Yoshida O, et al. Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 1995 ; 21 : 201-4.
PubMed
10) Inaba M, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 2002 ; 39 : 1261-9.
 
11) Yamada S, et al. Associations between physical activity, peripheral atherosclerosis and bone status in healthy Japanese women. Atherosclerosis 2006 ; 188 : 196-202.
PubMed
P.222 掲載の参考文献
1) Huntley AC. Cutaneous Manifestations of diabetes mellitus. In : Demis JD, ed. Clinical Dermatology. 24th Revision (1997). Lippincott-Raven ; 1996. unit 4-10, pp.1-14.
 
2) Yosipovitch G, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Daibetes Care 1998 ; 21 : 506-9.
 
3) Shemer A, et al. Diabetic dermopathy and internal complications in diabetes mellitus. Int J Dermatol 1998 ; 37 : 113-5.
PubMed
4) Binazzi M, Simonetti S. Granuloma annulare, necrobiosis lipoidica, and diabetic disease. Int J Dermatol 1988 ; 27 : 576-9.
PubMed
5) Yun JH, et al. Clinical and pathological features of generalized granuloma annulare with their correlation : a retrospective multicenter study in Korea. Ann Dermatol 2009 ; 21 : 113-9.
PubMed
6) Teraki Y, et al. Ketosis is involved in the origin of prurigo pigmentosa. J Am Acad Dermatol 1996 ; 34 : 509-11.
PubMed
7) 中村嘉男ほか. 糖尿病患者における手指硬化および手指拘縮の臨床的研究. 日本皮膚科学会雑誌2003 ; 113 : 1811-7.
 
8) 山本卓ほか. 糖尿病に伴う重症感染症. MB Derma 2003 ; 78 : 11-6.
 
P.228 掲載の参考文献
1) Tasali E, et al. Reduced sleep duration or quality : relationships with insulin resistance and type 2 diabetes. Prog Cardiovasc Dis 2009 ; 51 : 381-91.
 
2) Young T, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993 ; 328 : 1230-5.
PubMed
3) Shamsuzzaman AS, et al. Obstructive sleep apnea : implications for cardiac and vascular disease. JAMA 2003 ; 290 : 1906-14.
PubMed
4) Arnardottir ES, et al. Molecular signatures of obstructive sleep apnea in adults : a review and perspective. Sleep 2009 ; 32 : 447-70.
PubMed
5) Punjabi NM, et al ; Sleep Heart Health Study Investigators. Sleep-disordered breathing, glucose intolerance, and insulin resistance : the Sleep Heart Health Study. Am J Epidemiol 2004 ; 160 : 521-30.
 
6) Aronsohn RS, et al. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 2010 ; 181 : 507-13.
PubMed
7) Balkau B, et al ; Epidemiologic Study on the Insulin Resistance Syndrome Study Group. High baseline insulin levels associated with 6-year incident observed sleep apnea. Diabetes Care 2010 ; 33 : 1044-9.
 
8) Harsch IA, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004 ; 169 : 156-62.
PubMed
・ Spiegel K, et al. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009 ; 5 : 253-61.
PubMed
P.232 掲載の参考文献
1) Giovannucci E, et al. Diabetes and cancer : a consensus report. CA Cancer J Clin 2010 ; 60 : 207-21.
 
2) Vigneri P, et al. Diabetes and cancer. Endocr Relat Cancer 2009 ; 16 : 1103-23.
PubMed
3) Currie CJ, et al. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 ; 52 : 1766-77.
PubMed
4) Jonasson JM, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009 ; 52 : 1745-54.
PubMed
5) Colhoun HM ; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland : a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009 ; 52 : 1755-65.
 
6) Hemkens LG, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues : a cohort study. Diabetologia 2009 ; 52 : 1732-44.
 
7) Inoue M, et al. Diabetes mellitus and the risk of cancer : results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006 ; 166 : 1871-7.
PubMed
8) 清原裕 : 久山町スタディ. 糖尿病学の進歩 2003 ; 37 : 161-3.
 
9) Yamagata H, et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population : the Hisayama study. Diabetes Care 2005 ; 28 : 789-94.
 
・ El-Serag HB, et al. The association between diabetes and hepatocellular carcinoma : a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006 ; 4 : 369-80.
PubMed
・ Huxley R, et al. Type-II diabetes and pancreatic cancer : a meta-analysis of 36 studies. Br J Cancer 2005 ; 92 : 2076-83.
PubMed
・ Friberg E, et al. Diabetes mellitus and risk of endometrial cancer : a meta-analysis. Diabetologia 2007 ; 50 : 1365-74.
PubMed

6章 合併症治療のエビデンスと今後の展望

P.239 掲載の参考文献
1) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000 ; 342 : 381-9.
 
2) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
3) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002 ; 287 : 2563-9.
 
4) Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
5) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
PubMed
6) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
7) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS38. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 703-13.
Medical*Online
8) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS39. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 713-20.
Medical*Online
9) Holman RR, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 ; 359 : 1565-76.
PubMed
10) Sone H, et al. Long-term lifestyle intervention lowers incidence of stroke in Japanese patients with type 2 diabetes : nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010 ; 53 : 419-28.
PubMed
11) 曽根博仁ほか. Japan Diabetes Complications Study (JDCS). 日本糖尿病学会編. 糖尿病学の進歩 2010. 診断と治療社 ; 2010. pp.338-43.
 
12) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
13) Shichiri M, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000 ; 23 (Suppl 2) : B21-9.
 
14) Wake N, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes : a 10-year follow-up of the Kumamoto Study. Diabetes Res Clin Pract 2000 ; 48 : 201-10.
PubMed
15) Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
PubMed
16) Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
PubMed
P.243 掲載の参考文献
1) Nathan DM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 ; 353 : 2643-53.
PubMed
2) Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed
3) Yamagishi S, Imaizumi T. Diabetic vascular complications : pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005 ; 11 : 2279-99.
PubMed
4) Yamagishi S, et al. Receptor for advanced glycation end products (RAGE) : a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008 ; 14 : 487-95.
PubMed
5) Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
PubMed
6) Yamagishi S. Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA. Eur Heart J 2008 ; 29 : 1922.
PubMed
P.250 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン 2009. ライフサイエンス出版 ; 2009.
 
2) 大村隆夫ほか. 一般住民の22年間追跡調査における耐糖能異常と脳卒中発症の関連. 久山町研究. 糖尿病 1993 ; 36 : 17-24.
 
3) 中村陽介ほか. 耐糖能異常合併と血圧レベル別の心血管疾患死亡. 医学のあゆみ 2004 ; 210 : 717-8.
Medical*Online
4) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
5) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998 ; 317 : 713-20.
Medical*Online
6) Holman RR, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 ; 359 : 1565-76.
PubMed
7) Kawamori R, et al. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving longterm candesartan cilexetil therapy : Challenge-DM study. Diabetes Res Clin Pract 2009 ; 83 : 241-8.
PubMed
8) Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998 ; 351 : 1755-62.
 
P.256 掲載の参考文献
1) Stratton IM, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. BMJ 2000 ; 321 : 405-12.
 
2) 糖尿病における血管合併症の発症予防と進展抑制に関する研究 (JDC Study). 平成21年度総括分担研究報告.
 
3) Sattar N, et al. Statins and risk of incident diabetes : a collaborative meta-analysis of randomized statin trials. Lancet 2010 ; 375 : 735-42.
PubMed
4) Rajpathak SN, et al. Statin therapy and risk of developing type 2 diabetes : a metaanalysis. Diabetes Care 2009 ; 32 : 1924-9.
PubMed
5) ACCORD Study Group ; ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 ; 363 : 233-44.
 
6) American Diabetes Association. Standards of medical care in diabetes─2010. Diabetes Care 2010 ; 33 (Suppl 1) : S11-61.
 
7) Mabuchi H, et al ; J-LIT Study Group. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease : secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002 ; 66 : 1096-100.
 
8) Sone H, et al. Long-term lifestyle intervention lowers incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicenter randomized controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010 ; 53 : 419-28.
PubMed
・ Kamari Y, et al. Should all diabetic patients be treated with a statin? Diabetes Care 2009 ; 32 : S378-83.
PubMed
P.264 掲載の参考文献
1) 運動所要量・運動指針の策定検討会. 健康づくりのための運動指針2006-生活習慣病予防のために <エクササイズガイド 2006>. (http://www.mhlw.go.jp/bunya/kenkou/undou01/pdf/data.pdf)
 
2) 日本糖尿病学会編. 糖尿病治療ガイド 2010. 文光堂 ; 2010. pp.42-4.
 
・ 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010.
 
・ American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010 ; 33 (Suppl 1) : S26-7.
 
・ Sigal RJ, et al. Physical activity/exercise and type 2 diabetes : a consensus statement from the American Diabetes Association. Diabetes Care 2006 ; 29 : 1433-8.
PubMed
P.271 掲載の参考文献
1) 厚生労働省/最新たばこ情報/統計情報/成人喫煙率 (厚生労働省国民健康栄養調査). http://www.health-net.or.jp/tobacco/product/pd100000.html
 
2) Willi C, et al. Active smoking and the risk of type 2 diabetes : a systematic review and meta-analysis. JAMA 2007 ; 298 : 2654-64.
PubMed
3) Houston TK, et al. Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort : CARDIA study. BMJ 2006 ; 332 : 1064-9.
 
4) Montgomery SM, Ekbom A. Smoking during pregnancy and diabetes mellitus in a British longitudinal birth cohort. BMJ 2002 ; 324 : 26-7.
 
5) Yeh HC, et al. Smoking, smoking cessation, and risk for type 2 diabetes mellitus : a cohort study. Ann Intern Med 2010 ; 152 : 10-7.
PubMed
6) Muis MJ, et al. Determinants of daily insulin use in Type 1 diabetes. J Diabetes Complications 2006 ; 20 : 356-60.
PubMed
7) Saito K, et al. Risk imparted by various parameters of smoking in Japanese men with type 2 diabetes on their development of microalbuminuria : analysis from the Tsukuba Kawai Diabetes Registry. Diabetes Care 2007 ; 30 : 1286-8.
PubMed
8) Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care 2009 ; 32 (Suppl 2) : S429-31.
 
9) Adler AI, et al. UKPDS 59 : hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002 ; 25 : 894-9.
PubMed
10) 曽根博仁, 山田信博. 日本人2型糖尿病患者における血管合併症の発症予防と進展抑制に関する研究 : JDCS. 日本臨牀 2010 ; 68 : 865-71.
Medical*Online
P.276 掲載の参考文献
1) Kamiya H, et al. Polyol pathyway and protein kinase C activity of rat Schwannoma cells. Diabetes Metab Res Rev 2003 ; 19 : 131-9.
 
2) Hamada Y, et al. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon- (carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000 ; 23 : 1539-44.
PubMed
3) Hamada Y, et al. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients. Diabetes Care 1998 ; 21 : 1014-8.
PubMed
4) Watarai A, et al. Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients. Diabet Med 2006 ; 23 : 894-9.
PubMed
5) So WY, et al. Aldose reductase genotypes and cardiorenal complications : an 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care 2008 ; 31 : 2148-53.
PubMed
6) Hamada Y, Nakamura J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol 2004 ; 3 : 245-55.
PubMed
7) Hotta N, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006 ; 29 : 1538-44.
PubMed
8) Hotta N, et al ; ADCT Study Group. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008 ; 25 : 818-25.
 
9) Hotta N, et al ; SNK-860 Diabetic Neuropathy Study Group. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy : a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001 ; 24 : 1776-82.
 
10) Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006 ; 29 : 68-72
 
P.281 掲載の参考文献
1) Inoguchi T, et al. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats : differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992 ; 89 : 11059-63.
PubMed
2) Ishii H, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996 ; 272 : 728-31.
PubMed
3) Inoguchi T, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes 2000 ; 49 : 1939-45.
PubMed
4) Maeda Y, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 2010 ; 299 : F1328-38.
PubMed
5) Fujii M, et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 2007 ; 72 : 473-80.
PubMed
6) Inoguchi T, Nawata H. NAD (P) H oxidase activation : a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 2005 ; 6 : 495-501.
PubMed
7) Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010 ; 106 : 1319-31.
PubMed
8) PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy : initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKCDRS) multicenter randomized clinical trial. Diabetes 2005 ; 54 : 2188-97.
 
P.287 掲載の参考文献
1) Maillard LC. Action des acides amine's surles sucres : formation des m lano dines par voie m thodique. Comptes Pendus 1912 ; 66-7.
 
2) Takeuchi M, et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000 ; 6 : 114-25.
PubMed
3) Suzuki D, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999 ; 10 : 822-32.
PubMed
4) Koschinsky T, et al. Orally absorbed reactive glycation products (glycotoxins) : an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997 ; 94 : 6474-9.
PubMed
5) Schmidt AM, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992 ; 267 : 14987-97.
 
6) Neeper M, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992 ; 267 : 14998-5004.
PubMed
7) Araki N, et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995 ; 230 : 408-15.
PubMed
8) Ohgami N, et al. CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products. Ann N Y Acad Sci 2001 ; 947 : 350-5.
 
9) Ohgami N, et al. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 2001 ; 276 : 13348-55.
 
10) Jono T, et al. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 2002 ; 511 : 170-4.
PubMed
11) Vlassara H, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE) : a new member of the AGE-receptor complex. Mol Med 1995 ; 6 : 634-46.
PubMed
12) Tamura Y, et al. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 2002 ; 278 : 12613-7.
PubMed
13) Yamagishi S, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997 ; 272 : 8723-30.
PubMed
14) Tanaka N, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000 ; 275 : 25781-90.
PubMed
15) Yonekura H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003 ; 370 : 1097-109.
PubMed
16) Yamamoto Y, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001 ; 108 : 261-8.
PubMed
17) Yamamoto H. Mechanisms of vascular injury in diabetes : lessons from vascular cells in culture and transgenic animals. Biomed Rev 2000 ; 11 : 19-27.
 
18) Myint KM, et al. RAGE control of diabetic nephropathy in a mouse model : effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006 ; 55 : 2510-22.
 
19) Bolton WK, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004 ; 24 : 32-40.
PubMed
20) Nakamura S, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997 ; 46 : 895-9.
PubMed
21) Miyata T, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products : biochemical mechanisms. J Am Soc Nephrol 2002 ; 13 : 2478-87.
PubMed
22) van Boekel MA, et al. Glycation of human serum albumin : inhibition by Diclofenac. Biochim Biophys Acta 1992 ; 1120 : 201-4.
PubMed
23) Kalousova M, et al. Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 2004 ; 27 : 18-28.
PubMed
24) Horiuchi T, Kurokawa T. Purification and properties of fructosylamine oxidase from Aspergillus sp. 1005. Agric Biol Chem 1991 ; 55 : 333-8.
 
25) Vasan S, et al. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003 ; 419 : 89-96.
PubMed
26) Wilkinson-Berka JL, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat. Diabetes 2002 ; 51 : 3283-9.
PubMed
27) Cheng C, et al. Enhanced scavenging of lipid substances is a possible effect of corticosteroids in the treatment of cholesterol crystal embolism. Pathol Res Pract 2006 ; 202 : 591-8.
PubMed
28) Harashima A, et al. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products : structure, function and expression. Biochem J 2006 ; 396 : 109-15.
PubMed
29) Koyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005 ; 25 : 2587-93.
PubMed
30) Katakami N, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients : its possible association with diabetic vascular complications. Diabetes Care 2005 ; 28 : 2716-21.
PubMed
31) Forbes JM, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005 ; 16 : 2251-3.
 
32) Tan KC, et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007 ; 50 : 1819-25.
PubMed
P.296 掲載の参考文献
1) Giardino I, et al. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996 ; 97 : 1422-8.
PubMed
2) Nishikawa T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000 ; 404 : 787-90.
PubMed
3) Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal 2007 ; 9 : 343-53.
PubMed
4) Kukidome D, et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006 ; 55 : 120-7.
PubMed
5) Nishikawa T, et al. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003 ; 26 : 1507-12.
PubMed
6) Araki E, et al. Oxidative stress : A cause and therapeutic target of diabetic complications. J Diabetes Invest 2010 ; 1 : 90-6.
 
7) Goto H, et al. Endothelial MnSOD overexpression prevents retinal VEGF expression in diabetic mice. Biochem Biophys Res Commun 2008 ; 366 : 814-20.
PubMed
8) Cook NR, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women : results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007 ; 167 : 1610-8.
 
9) Milman U, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype : a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008 ; 28 : 341-7.
 
10) Lu C, et al. Resveratrol blocks high glucose-induced mitochondrial reactive oxygen species production in bovine aortic endothelial cells : role of phase 2 enzyme induction? Diabetes Obes Metab 2008 ; 10 : 347-9.
PubMed
P.301 掲載の参考文献
1) Qiao Q, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000 ; 43 : 1470-5.
PubMed
2) 山崎勝也, 小林正. 糖尿病予防のための戦略研究課題 2 (J-DOIT2) とは何か-その意義と展望. プラクティス 2007 ; 24 : 417-23.
 
3) 伊藤千賀子. 組織学的な糖尿病対策の現状-日本糖尿病対策推進会議. 日本糖尿病学会編. 糖尿病学の進歩. 第41集. 診断と治療社 ; 2007. pp.232-7.
 

書評

最近チェックした商品履歴

Loading...